Skip to main content

Advertisement

SpringerLink
Log in

Post Partial Nephrectomy Surveillance Imaging: an Evidence-Based Approach

  • New Imaging Techniques (A Rastinehad and S Rais-Bahrami, Section Editors)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

To ensure the early detection of recurrent disease, all patients should undergo routine surveillance following partial nephrectomy for renal cell carcinoma. In order to optimize resource allocation and avoid unnecessary radiation exposure, the frequency and duration of surveillance should be tailored to the individual patient’s risk of cancer recurrence. The evidence for surveillance after partial nephrectomy is presented reviewing the current literature on prognostic models and proposed surveillance protocols based on the timing and patterns of renal cell carcinoma recurrence. In addition, we review recent guidelines on post partial nephrectomy surveillance as well as the literature on novel imaging techniques that may aid in early disease discovery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin. 2014;64:9–29.

    Google Scholar 

  2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer J Int du Cancer. 2010;127:2893–917.

    Article  CAS  Google Scholar 

  3. Gill IS, Aron M, Gervais DA, Jewett MA. Clinical practice. Small renal mass. N Engl J Med. 2010;362:624–34.

    Article  CAS  PubMed  Google Scholar 

  4. Miller DC, Saigal CS, Banerjee M, Hanley J, Litwin MS. Urologic Diseases in America P. Diffusion of surgical innovation among patients with kidney cancer. Cancer. 2008;112:1708–17.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Woldrich JM, Palazzi K, Stroup SP, Sur RL, Parsons JK, Chang D, et al. Trends in the surgical management of localized renal masses: thermal ablation, partial and radical nephrectomy in the USA, 1998–2008. BJU Int. 2013;111:1261–8.

    Article  PubMed  Google Scholar 

  6. Poon SA, Silberstein JL, Chen LY, Ehdaie B, Kim PH, Russo P. Trends in partial and radical nephrectomy: an analysis of case logs from certifying urologists. J Urol. 2013;190:464–9.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Weight CJ, Larson BT, Fergany AF, Gao T, Lane BR, Campbell SC, et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. J Urol. 2010;183:1317–23.

    Article  PubMed  Google Scholar 

  8. Kim SP, Thompson RH, Boorjian SA, Weight CJ, Han LC, Murad MH, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol. 2012;188:51–7.

    Article  PubMed  Google Scholar 

  9. Mariusdottir E, Jonsson E, Marteinsson VT, Sigurdsson MI, Gudbjartsson T. Kidney function following partial or radical nephrectomy for renal cell carcinoma: a population-based study. Scand J Urol. 2013;47:476–82.

    Article  PubMed  Google Scholar 

  10. Yap SA, Finelli A, Urbach DR, Tomlinson GA, Alibhai SM. Partial Nephrectomy for the Treatment of Renal Cell Carcinoma and the Risk of End Stage Renal Disease. BJU Int. 2014.

  11. Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182:1271–9.

    Article  PubMed  Google Scholar 

  12. Motzer RJE, Agarwal N, Beard C, Bhayani S, Bolger G, Chang S, Choueiri T, Derweesh I, Gupta S, Hancock S, Kim J, Kuzel T, Lam E, Lau C, Levine E, Lin D, Michaelson D, Olencki T, Pili R, Plimack E, Rampersaud E, Redman B, Ryan C, Sheinfeld J, Sircar K, Somer B, Wilder R. NCCN Guideline Kidney Cancer. http://www.nccn.org/professionals/physician_gls/f_guidelines_nojava.asp-site. 2014. Current gudeline from the NCCN on the managment of renal cell carcinoma.

  13. Ljungberg BBK, Bex A, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk M, Lam T, Marconi L, Merseburger L, Mulders P, Powles T, Staehler M, Volpe A, Renal Cell Cancer Guidelines. 2014. The 2014 guideline from the EAU proposes an algorithm for surveillance based risk-stratification using one of the validated classification systems.

  14. Dabestani S, Marconi L, Hofmann FSF, Lam T, Canfield S, Staehler M, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014;15:e549–61.

    Article  PubMed  Google Scholar 

  15. Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, et al. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer. 2014;110:2821–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27:3584–90.

    Article  CAS  Google Scholar 

  17. Lipsky MJ, Shapiro EY, Hruby GW, McKiernan JM. Diagnostic radiation exposure during surveillance in patients with pT1a renal cell carcinoma. Urology. 2013;81:1190–5.

    Article  PubMed  Google Scholar 

  18. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63–7.

    Article  CAS  PubMed  Google Scholar 

  19. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005;173:48–51.

    Article  PubMed  Google Scholar 

  20. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97:1663–71.

    Article  PubMed  Google Scholar 

  21. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Leibovich BC, et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol. 2003;170:2225–32.

    Article  PubMed  Google Scholar 

  22. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2002;20:4559–66.

    Article  Google Scholar 

  23. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005;174:466–72. discussion 72; quiz 801.

    Article  PubMed  Google Scholar 

  24. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol. 2011;60:644–61.

    Article  PubMed  Google Scholar 

  25. Heidenreich A, Schrader AJ, Varga Z. Basic science and research in renal cell carcinoma: from workbench to bedside. Curr Opin Urol. 2003;13:457–62.

    Article  PubMed  Google Scholar 

  26. Small AC, Gong Y, Oh WK, Hall SJ, van Rijn CJ, Galsky MD. The emerging role of circulating tumor cell detection in genitourinary cancer. J Urol. 2012;188:21–6.

    Article  PubMed  Google Scholar 

  27. Antonelli A, Cozzoli A, Zani D, Zanotelli T, Nicolai M, Cunico SC, et al. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int. 2007;99:296–300.

    Article  PubMed  Google Scholar 

  28. Hafez KS, Novick AC, Campbell SC. Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol. 1997;157:2067–70.

    Article  CAS  PubMed  Google Scholar 

  29. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998;159:1163–7.

    Article  CAS  PubMed  Google Scholar 

  30. Ljungberg B, Alamdari FI, Rasmuson T, Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int. 1999;84:405–11.

    Article  CAS  PubMed  Google Scholar 

  31. Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol. 1995;154:28–31.

    Article  CAS  PubMed  Google Scholar 

  32. Siddiqui SA, Frank I, Cheville JC, Lohse CM, Leibovich BC, Blute ML. Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol. BJU Int. 2009;104:778–85.

    Article  PubMed  Google Scholar 

  33. Stephenson AJ, Chetner MP, Rourke K, Gleave ME, Signaevsky M, Palmer B, et al. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol. 2004;172:58–62.

    Article  PubMed  Google Scholar 

  34. Brookman-May S, May M, Shariat SF, Xylinas E, Stief C, Zigeuner R, et al. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Eur Urol. 2013;64:472–7.

    Article  PubMed  Google Scholar 

  35. Adamy A, Chong KT, Chade D, Costaras J, Russo G, Kaag MG, et al. Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol. 2011;185:433–8.

    Article  PubMed  Google Scholar 

  36. Khalifeh A, Kaouk JH, Bhayani S, Rogers C, Stifelman M, Tanagho YS, et al. Positive surgical margins in robot-assisted partial nephrectomy: a multi-institutional analysis of oncologic outcomes (leave no tumor behind). J Urol. 2013;190:1674–9.

    Article  PubMed  Google Scholar 

  37. Donat SM, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, Herrell SD III, Hilton S, Jonasch E, Lin DW, Reuter VE, Chang SS. Follow-up for clinically localized renal neoplasms: AUA guideline. 2013. The AUA guidelines on the surveillance of patients with clinically-localized RCC after treatment with surgery or ablative procedures. The recommendations are based on a well conducted systematic review of the literature.

  38. Stewart F, Thompson H, Psutka S, Cheville J, Lohse C, Boorjian S, Leibovich B. Evaluation of the National Comprehensive Cancer Network and American Urological Association Renal Cell Carcinoma Surveillance Guidelines. J Clin Oncol. 2014. in press.

  39. Wang HY, Ding HJ, Chen JH, Chao CH, Lu YY, Lin WY, et al. Meta-analysis of the diagnostic performance of [18 F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging : Off Publ Int Cancer Imaging Soc. 2012;12:464–74.

    Article  Google Scholar 

  40. Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2003;21:3995–4000.

    Article  Google Scholar 

  41. Kumar R, Shandal V, Shamim SA, Jeph S, Singh H, Malhotra A. Role of FDG PET-CT in recurrent renal cell carcinoma. Nucl Med Commun. 2010;31:844–50.

    PubMed  Google Scholar 

  42. Nakatani K, Nakamoto Y, Saga T, Higashi T, Togashi K. The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Eur J Radiol. 2011;79:29–35.

    Article  PubMed  Google Scholar 

  43. Divgi CR, Uzzo RG, Gatsonis C, Bartz R, Treutner S, Yu JQ, et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31:187–94. A prospective fully-paired direct comparison of girentuximab PET/CT to multiphasic contrast-enhanced CT to characterize renal masses.

    Article  Google Scholar 

  44. Povoski SP, Hall NC, Murrey Jr DA, Sharp DS, Hitchcock CL, Mojzisik CM, et al. Multimodal imaging and detection strategy with 124 I-labeled chimeric monoclonal antibody cG250 for accurate localization and confirmation of extent of disease during laparoscopic and open surgical resection of clear cell renal cell carcinoma. Surg Innov. 2013;20:59–69.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Stillebroer AB, Boerman OC, Desar IM, Boers-Sonderen MJ, van Herpen CM, Langenhuijsen JF, et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2013;64:478–85.

    Article  CAS  PubMed  Google Scholar 

  46. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496–507.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with ethics guidelines

ᅟ

Conflict of interest

Dr. Lorenzo Marconi, Dr. Michael A. Gorin, and Dr. Mohamad E. Allaf each declare no potential conflicts of interest

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Urology and Renal Transplantation Department, Coimbra University Hospital, Coimbra, Portugal

    Lorenzo Marconi

  2. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Park 223, Baltimore, MD, 21287, USA

    Michael A. Gorin & Mohamad E. Allaf

Authors
  1. Lorenzo Marconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael A. Gorin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamad E. Allaf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamad E. Allaf.

Additional information

This article is part of Topical Collection on New Imaging Techniques

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marconi, L., Gorin, M.A. & Allaf, M.E. Post Partial Nephrectomy Surveillance Imaging: an Evidence-Based Approach. Curr Urol Rep 16, 23 (2015). https://doi.org/10.1007/s11934-015-0489-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-015-0489-7

Keywords

Search

Navigation